OncoMatch/Clinical Trials/NCT06494150
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
Is NCT06494150 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including nab-Sirolimus and Fulvestrant for low grade ovarian serous adenocarcinoma.
Treatment: nab-Sirolimus · Fulvestrant — This single arm phase II study proposes to evaluate the efficacy and safety of nab-sirolimus + endocrine therapy (Fulvestrant) in patients with recurrent low grade serous ovarian cancer (LGSOC).
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: mTOR inhibitor (nab-sirolimus, sirolimus, temsirolimus)
Patients who have previously received nab-sirolimus, any other mTOR inhibitor or any agent targeting the PI3K/AKT/mTOR pathway.
Cannot have received: PI3K/AKT/mTOR pathway inhibitor
Patients who have previously received...any agent targeting the PI3K/AKT/mTOR pathway.
Lab requirements
Blood counts
Adequate bone marrow function as defined by the protocol.
Kidney function
Adequate renal function as defined by the protocol.
Liver function
Adequate hepatic function as defined by the protocol.
Adequate bone marrow, hepatic and renal function as defined by the protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- OU Health Stephenson Cancer Center · Oklahoma City, Oklahoma
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify